Beam Therapeutics (BEAM) Accumulated Expenses (2019 - 2026)

Beam Therapeutics (BEAM) has reported Accumulated Expenses for 8 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 21.31% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (up 21.31% YoY), while the FY2025 annual figure was $55.3 million, up 156.2% from the prior year.
• Accumulated Expenses slipped to $6.7 million in Q1 2026 per BEAM's latest filing, from $55.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $111.7 million in Q4 2023 and bottomed at $4.9 million in Q1 2024.
• Historically, Accumulated Expenses has averaged $31.1 million across 5 years, with a median of $24.1 million in 2022.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 400.46% — and 2024, when it plunged 80.68%.
• Beam Therapeutics' Accumulated Expenses stood at $49.9 million in 2022, then jumped by 123.72% to $111.7 million in 2023, then slumped by 80.68% to $21.6 million in 2024, then surged by 156.2% to $55.3 million in 2025, then slumped by 87.92% to $6.7 million in 2026.
• Business Quant data shows BEAM's Accumulated Expenses at $6.7 million in Q1 2026, $55.3 million in Q4 2025, and $16.5 million in Q3 2025.